Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction:...

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• ST-segment elevation myocardial infarction (STEMI) is a critical cardiovascular condition.
• Systemic inflammation plays a significant role in STEMI pathophysiology and outcomes.
• Interleukin-1 (IL-1) is a key mediator of inflammation.

Purpose of the Study:

• To evaluate the effect of goflikicept, an IL-1 blocker, on systemic inflammation in STEMI patients.
• To assess secondary outcomes including cardiac function and clinical endpoints at 1 year.
• To report biomarker analyses at 28 days post-treatment.

Main Methods:

• A randomized, double-blinded clinical trial involving STEMI patients.
• Patients received a single administration of goflikicept (80 mg or 160 mg) or placebo.
• Systemic inflammation was measured by the area under the curve (AUC) for high-sensitivity C-reactive protein (hs-CRP) and natriuretic peptides.

Main Results:

• Both doses of goflikicept significantly reduced hs-CRP AUC at 28 days compared to placebo.
• No significant differences were observed between goflikicept doses.
• No significant differences were found in natriuretic peptide AUC, mortality, cardiovascular hospitalizations, heart failure events, diuretic use, or adverse events between groups.

Conclusions:

• Goflikicept effectively reduces systemic inflammation in STEMI patients.
• The treatment was well-tolerated at both 80 mg and 160 mg doses.
• Larger trials are required to determine if IL-1 blockade with goflikicept translates to improved clinical outcomes in STEMI.